A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation                                                                     (full – 2003)  http://molpharm.aspetjournals.org/content/64/6/1334.full


The endocannabinoid system in chronic liver disease                      (full – 2005)



(Marijuana/Hash) Endocannabinoids and liver disease – review                      (full – 2005)



Antifibrogenic role of the cannabinoid receptor CB2 in the liver.                    (abst – 2005)



Cannabis use improves retention and virological outcomes in patients treated for hepatitis C        (full – 2006)                     http://www.natap.org/2006/HCV/091506_02.htm


Study: Pot Helps Hepatitis Treatment                      (news – 2006)



Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases                                                                      (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376822/?tool=pmcentrez


Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids : Involvement of Regulatory T Cells                                                                    (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828293/?tool=pmcentrez










Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.  (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662895/?tool=pmcentrez


Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats            (full – 2008)  http://jpet.aspetjournals.org/content/324/2/475.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=  cannabinoid&searchid=1&FIRSTINDEX=320&resourcetype=HWCIT#content-block


Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects      (abst – 2008)                          http://gut.bmj.com/content/57/8/1140.abstract


Endocannabinoids in liver disease and hepatic encephalopathy.               (abst – 2008)



Should Hepatitis C Patients Who Smoke Marijuana Be Eligible For Liver Transplants? (news – 2008)                                       http://www.sciencedaily.com/releases/2008/10/081022211032.htm


Cannabinoids as novel anti-inflammatory drugs.              (full – 2009)



US Patent Application 20090005461 – Use of Cannabidiol in the Treatment of Hepatitis (full – 2009)                                      http://www.patentstorm.us/applications/20090005461/fulltext.html


The role of CB2 cannabinoid receptor and Leptin in hepatic fibrosis via lymphocyte alterations and HSC phagocytosis                                                  (abst – 2009)  http://www.docstoc.com/docs/76792678/The-role-of-CB2-cannabinoid-receptor-and-Leptin-in-hepatic-


Use of Cannabinoids as a Novel Therapeutic Modality Against Autoimmune Hepatitis (abst – 2009)                                     http://www.ncbi.nlm.nih.gov/pubmed/19647124


Medical Marijuana and Hepatitis C                (news – 2009)



Medical Marijuana and Viral Hepatitis                 (news – 2009)



Endocannabinoids in liver disease.                  (full – 2011)



Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental Autoimmune Hepatitis Following Activation of TRPV1 Receptors by Cannabidiol (full – 2011)         http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069975/?tool=pmcentrez









Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis.                                                                     (full – 2011)  http://www.nature.com/cddis/journal/v2/n6/pdf/cddis201152a.pdf


Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/


Cannabis Compound Induces Death Of Cells Associated With Liver Fibrosis (news – 2011)                                             http://www.norml.org/index.cfm?Group_ID=8615


The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes

(abst – 2012)                           http://ajpgi.physiology.org/content/302/8/G873.abstract?rss=1


Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems                                                                                        (abst – 2012)  http://jpet.aspetjournals.org/content/340/3/629.abstract?sid=ae58f15a-06bb-4a81-b850-61bb89fd59f5


Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography-Mass Spectrometry.

(abst – 2012)                     http://www.ncbi.nlm.nih.gov/pubmed/22946841


Share a link for